Integrating Artificial Intelligence Into Lung Cancer Screening. (DACAPO)
A Randomized Controlled Study of Including a Deep Learning-based Analysis of Chest Computed Tomography as an Aid to Decision Making of Multidisciplinary Team Meetings for Lung Cancer Screening in Eligible Patients
Lung cancer (LC) screening using low-dose chest CT (LDCT) has already proven its efficacy.
The mortality reduction associated with LC screening is around 20%, much higher than the reduction in mortality associated with screening for breast, colon or prostate cancers.
Implementing lung cancer screening on a large scale faces two main obstacles:
- The lack of thoracic radiologists and LDCT necessary for the eligible population (between 1.6 and 2.2 million people in France);
- The high frequency of false positive screenings: in the NLST trial, more than 20% of the subjects screened were found to have at least one nodule of an indeterminate lung nodule (ILN) whereas less than 3% of ILNs are actually LC.
The gold standard for determining on the benign or malignant nature of a nodule is definitive histology. Otherwise, the evolution of the nodule on serial thoracic imaging is a good alternative. The period of indeterminacy of a nodule can be as long as 24 months in many cases, which can be a source of prolonged and sometimes unjustified anxiety for screening candidates.
The purpose of this randomized controlled study that focuses on LC screening in patients aged 50 to 80 years, who smoked more than 20 packs/ year or stopped smoking less than 15 years ago. Its objective is to determine whether assisting multidisciplinary team (MDT) meetings with an AI-based analysis of screening LDCT accelerates the definitive classification of nodules into malignant or benign.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marquette Charles-Hugo, PhD
- Phone Number: +33492037777
- Email: marquette.c@chu-nice.fr
Study Contact Backup
- Name: Boutros Jacques
- Phone Number: +33492037777
- Email: boutros.j@chu-nice.fr
Study Locations
-
-
Alpes-maritimes
-
Nice, Alpes-maritimes, France, 06001
- Recruiting
- CHU de Nice - Hôpital de Pasteur
-
Contact:
- Marquette Charles-Hugo, PhD
- Phone Number: +33492037777
- Email: marquette.c@chu-nice.fr
-
Contact:
- Boutros Jacques
- Phone Number: +33492037777
- Email: boutros.j@chu-nice.fr
-
Principal Investigator:
- Marquette Charles-Hugo, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 50 and 80 years old
- active smoker or ex-smoker who quit smoking less than 15 years ago
- smoking history of at least 20 pack-years
- signature of the informed consent
- affiliation to French social security
Exclusion Criteria:
- clinical signs suggestive of cancer
- recent chest scan (<1 year) for another cause
- radiological abnormality requiring follow-up or additional investigations
- health problem significantly limiting life expectancy from the clinician's point of view
- health problem limiting ability or willingness to undergo lung surgery
- Patients with active neoplasia, except basal cell carcinoma of the skin.
- vulnerable people: adults under guardianship, adults under curatorship medical and/or psychiatric problems of sufficient severity to limit full adherence to the study or expose patients to excessive risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: IA Group
Patients with at least one nodule (> 6mm) for whom the multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
|
The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
|
|
Other: Group not IA analysis
Patients with at least one nodule (> 6mm) for whom the multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
|
The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnosis of lung disease
Time Frame: At 3 years
|
Elapsed time between lung nodule discovery and MDT decision making.
|
At 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Operating characteristics of Ai-based strategy
Time Frame: At 3 years
|
At 3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marquette Charles-Hugo, CHU de Nice, Service de Pneumologie
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-PP-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.